The use of
angiotensin converting enzyme inhibitors, or ACE-I, in selected patients with stable angina pectoris is associated with
decreased future cardiovascular events. Such patients include
those with left ventricular ejection fractions of 40% or less, hypertension, diabetes, and chronic kidney disease. When any of the latter three conditions are present, ACE-I may be used independent of the patient's ejection fraction. For
those intolerant of ACE-I, an angiotensin receptor blocker (ARB) is recommended.
You may now choose further discussion of anticoagulation with atrial fibrillation or proceed to the next section.